Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lum

Showing results (211-220 of 253) with videos related to

Pageof 26
Sort By:
Substance Abuse|January 19, 2021
Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addictionHolly N Hagle, Marlene Martin, Rachel Winograd, et al.
Scientific Reports|October 16, 2025
Modelling of immune infiltration in prostate cancer treated with HDR-brachytherapy using Raman spectroscopy and machine learningSandra N Popescu, Kirsty Milligan, Mitchell Wiebe, et al.
Molecular Therapy. Methods & Clinical Development|March 14, 2022
Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular functionSarah MacPherson, Sarah Keyes, Marisa K Kilgour, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphineP Todd Korthuis, David A Fiellin, Rongwei Fu, et al.
Addiction (Abingdon, England)|January 7, 2017
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trialPhilip T Korthuis, Paula J Lum, Pamela Vergara-Rodriguez, et al.
Contemporary Clinical Trials|November 1, 2019
Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO studyAlain H Litwin, John Jost, Katherine Wagner, et al.
Nature Protocols|August 19, 2022
Principles of reproducible metabolite profiling of enriched lymphocytes in tumors and ascites from human ovarian cancerMarisa K Kilgour, Sarah MacPherson, Lauren G Zacharias, et al.
The Journal of Pathology|August 29, 2012
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancerJaeline E Spowart, Katelin N Townsend, Hassan Huwait, et al.
Drug and Alcohol Dependence|February 25, 2025
Improvement in anxiety symptoms during treatment of Hepatitis C in people who inject drugs: The HERO studyJessica Obeysekare, Irene Pericot-Valverde, Snehal Lopes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxoneDavid A Fiellin, Linda Weiss, Michael Botsko, et al.
Pageof 26

Showing results (211-220 of 253) with videos related to

Sort By:
Pageof 26
Substance Abuse|January 19, 2021
Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addictionHolly N Hagle, Marlene Martin, Rachel Winograd, et al.
Scientific Reports|October 16, 2025
Modelling of immune infiltration in prostate cancer treated with HDR-brachytherapy using Raman spectroscopy and machine learningSandra N Popescu, Kirsty Milligan, Mitchell Wiebe, et al.
Molecular Therapy. Methods & Clinical Development|March 14, 2022
Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular functionSarah MacPherson, Sarah Keyes, Marisa K Kilgour, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphineP Todd Korthuis, David A Fiellin, Rongwei Fu, et al.
Addiction (Abingdon, England)|January 7, 2017
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trialPhilip T Korthuis, Paula J Lum, Pamela Vergara-Rodriguez, et al.
Contemporary Clinical Trials|November 1, 2019
Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO studyAlain H Litwin, John Jost, Katherine Wagner, et al.
Nature Protocols|August 19, 2022
Principles of reproducible metabolite profiling of enriched lymphocytes in tumors and ascites from human ovarian cancerMarisa K Kilgour, Sarah MacPherson, Lauren G Zacharias, et al.
The Journal of Pathology|August 29, 2012
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancerJaeline E Spowart, Katelin N Townsend, Hassan Huwait, et al.
Drug and Alcohol Dependence|February 25, 2025
Improvement in anxiety symptoms during treatment of Hepatitis C in people who inject drugs: The HERO studyJessica Obeysekare, Irene Pericot-Valverde, Snehal Lopes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxoneDavid A Fiellin, Linda Weiss, Michael Botsko, et al.
Pageof 26